ReviewCureus2025
Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.PLoS medicine · 2026 · on this mapPooled it
- A systematic review of semaglutide-associated kidney injury case reports.Frontiers in medicine · 2026Pooled it
- Psychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Pathogenesis of Non-Arteritic Anterior Ischemic Optic Neuropathy Associated with COVID-19.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review examines the potential association between semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and the development of non-arteritic anterior ischemic optic neuropathy (NAION). Nine studies were included, consisting of retrospective cohort analyses, case series, and pharmacovigilance reports. Findings across the literature were inconsistent, with some studies reporting an increased risk while others found no significant association. Variations in study design, diagnostic criteria, and population characteristics limited comparability and prevented meta-analysis. Overall, the absolute risk appears to be low, and the therapeutic benefits of semaglutide in managing type 2 diabetes and obesity are likely to outweigh potential ocular concerns for most patients. Clinicians should exercise caution in individuals with predisposing ocular risk factors, such as small Bruch's membrane opening (BMO), optic disc drusen (ODD), or otherwise crowded optic nerve heads. Further prospective studies with rigorous ophthalmologic evaluation are needed to clarify any causal relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.